Kyverna Therapeutics Inc (KYTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.25-1.20%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KYTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KYTX — credit agreement
Dated 2026-07-09
Entry into a Material Definitive Agreement. As previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (the “Collateral Agent”), and certain lenders from time to time party thereto (the “Lenders”). The Loan and Security Agreement provides a non-dilutive term loan facility (the “Loan Facility”) of up to an aggregate principal amoun…
Why it matters: How Kyverna does financially shows if it can keep its cash and support projects.
Watch forKyverna has a net loss that is better than expected. This shows better financial management.
Also watch forThe net loss is worse than expected. This raises worries about financial stability.
Why it matters: Funding the SPS BLA filing is key for future growth and product development.
Supportive ifAnnouncement of funding secured for the SPS BLA filing.
Worry ifNo funding secured for the SPS BLA filing.
Why it matters: Successful scaling of miv-cel production is crucial for commercial launch readiness. Issues could delay launch plans.
Supportive ifElevateBio hits its production goals for miv-cel. This is before the product launch.
Worry ifProduction issues arise that delay the launch of miv-cel.
Why it matters: Updates on the PMS strategy will explain miv-cel's role in treating multiple sclerosis. This could affect future growth.
Watch forThe company will give a full update on its PMS strategy by early 2027.
Also watch forNo update is provided by early 2027 or the update is not favorable.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$257 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $886 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,716 loss on $10,000 · 37.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Successful commercial readiness is key for a smooth miv-cel launch. This includes hiring and supply deals.
Supportive ifThe company will fill key commercial roles and set up supply agreements by Q4 2026.
Worry ifThere may be big delays or issues with getting ready for the market.
Why it matters: Keeping a strong cash position is important. It helps fund trials and operations without dilution.
Worry ifKyverna reports cash reserves above $200 million in the next earnings call.
Less concerning ifCash reserves fall below $200 million without a clear plan for funding.
Why it matters: Updates on miv-cel's progress for non-active PMS can change its market potential. This can also affect how investors see it.
Watch forKyverna will share good news on miv-cel's PMS strategy and clinical data in Q4 2026.
Also watch forThere are no big updates or bad news on miv-cel's PMS strategy in Q4 2026.
Why it matters: Earnings show the company's money health and ability to reach growth goals.
Watch forEarnings are better than expected, showing strong results.
Also watch forEarnings did not meet expectations. This shows possible problems in operations or market conditions.
Why it matters: Progress on this trial is crucial for future growth and funding. Delays can raise concerns.
Supportive ifManagement shares good news about the Phase 3 gMG trial. They have reached important milestones.
Worry ifManagement announces delays or setbacks in the Phase 3 gMG trial.
Why it matters: Progress in the gMG trial is key for Kyverna's plans and possible earnings.
Supportive ifKyverna says it has finished enrolling patients in the Phase 3 trial for gMG.
Worry ifEnrollment slows down or is delayed past current timelines.
Why it matters: Maintaining cash into 2028 is crucial for ongoing operations and growth plans.
Worry ifManagement says cash will last past 2028.
Less concerning ifCash runway projected to end before 2028.
Why it matters: This submission is key for Kyverna's first potential FDA approval. It could lead to the launch of miv-cel for stiff person syndrome.
Supportive ifThe rolling BLA submission for miv-cel is completed by Q4 2026 as planned.
Worry ifThe submission is delayed beyond Q4 2026.
Why it matters: This data shows how well miv-cel works. It may affect future approvals and how the market sees it.
Watch forPositive data from KYSA-8 shows miv-cel works well.
Also watch forNegative data from KYSA-8 raises doubts about how well miv-cel works.